We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fatty Acids Profiles Related to Biomarkers in GDM Progression

By LabMedica International staff writers
Posted on 25 Nov 2021
Print article
Image: The Hewlett Packard HP 5890 Series II Plus Gas Chromatograph (GC) System (Photo courtesy of American Laboratory Trading)
Image: The Hewlett Packard HP 5890 Series II Plus Gas Chromatograph (GC) System (Photo courtesy of American Laboratory Trading)
Gestational diabetes mellitus (GDM) is a condition in which a hormone made by the placenta prevents the body from using insulin effectively. Glucose builds up in the blood instead of being absorbed by the cells.

Fatty acids (FAs) are mainly composed of plasma phospholipids, cholesterol esters, triglycerides, and erythrocyte total phospholipids, all of which have been implicated in the pathogenesis of cardiometabolic disorders via their associations with insulin resistance, β-cell dysfunction, inflammation, glucose transporter inhibition, and lipotoxicity.

A team of medical scientists led by those at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Bethesda, MD, USA) recruited from a large cohort of 2,802 pregnant women, 85 GDM cases using the Carpenter and Coustan criteria and 85 non-GDM controls after exclusion. Upon enrollment at 8 to 13 weeks gestational age (GA) (visit 0), women were scheduled to attend five follow-up visits with blood collection at targeted weeks of GA.

The team examined three subclasses of plasma phospholipid FAs, including plasma phospholipid saturated FA (SFAs), polyunsaturated FA (PUFAs), and monounsaturated FAs (MUFAs) via the Hewlett Packard 5890 gas chromatography system (Palo Alto, CA, USA). The content of individual SFAs, PUFAs, and MUFAs was expressed as weight percentage of the total plasma phospholipid FAs. They assayed all case-control matched samples in a random order in the same analytic run and then performed 40 repeats in each batch among the in-house pooled control samples from the same cohort to assess the interassay CV.

The investigators reported that eight FAs showed significant fold changes from the baseline values (23–31 weeks) among GDM cases as compared to women without GDM. Five FAs showed reduced fold changes: myristic acid (14:0), palmitic acid (16:0), cis-palmitoleic acid (16:1n7), alpha-linolenic acid (18:3n3), and dihomo-gamma-linoleic acid (20:3n6), whereas three showed increases: heptadecanoic acid (17:0), cis-vaccenic acid (18:1n7), and arachidonic acid (20:4n6).

The authors concluded that they had identified eight plasma phospholipid FAs [SFAs: myristic acid (14:0), palmitic acid (16:0), and heptadecanoic acid (17:0); PUFAs: ALA (18:3n3), DGLA (20:3n6), and AA (20:4n6); MUFAs: palmitoleic acid (16:1n7) and vaccenic acid (18:1n7)] with unique patterns of change before and after GDM diagnosis. Such changes of FAs differed significantly between women with and without GDM during the same time window in pregnancy. The study was published on October 11, 2021 in the journal Clinical Chemistry.

Related Links:
National Institute of Child Health and Human Development
Hewlett Packard


New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
Silver Supplier
3-Part Diff Hematology Analyzer
Abacus Junior 30
New
Chemiluminescence Analyzer
DZ-Lite 3000 Plus
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus

Print article

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.